Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Data further support OSE-127’s potential in chronic inflammatory bowel diseasesConfirm novel and differentiated mechanism of action of OSE-127, currently being investigated in an ongoing Phase 1 trial...
-
NANTES, France, April 09, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announces that it has strengthened its intellectual property rights for its Phase...
-
Oral presentation highlights investigator case reports showing early signs of activity of Tedopi® in patients with non-small cell lung cancer in third-line treatment after checkpoint inhibitor...
-
Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseasesOSE’s partnership business model based on innovative products; Multiple...
-
NANTES, France, March 26, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), announces a new research collaboration agreement with premier cancer research hospital,...
-
NANTES, France, March 07, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), announces that it has disclosed its novel bispecific checkpoint inhibitor (BiCKI®)...
-
First-in-class SIRPα checkpoint inhibitorDiscovered and validated on OSE's immune target discovery platform NANTES, France, March 05, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:...
-
Oral presentation will highlight early signs of activity of Tedopi® from the ongoing Phase 3 trial in Non-Small Cell Lung Cancer NANTES, France, Feb. 28, 2019 (GLOBE NEWSWIRE) -- OSE...
-
Servier exercised first of two steps under OSE-127 global licensing option agreement OSE-127, an IL-7R antagonist, is currently in Phase 1 clinical testing NANTES, France and PARIS, Feb. 07,...
-
Granted by the Japanese Patent OfficeFurther Strengthens Global Intellectual Property Portfolio for Tedopi® in Immuno-Oncology NANTES, France, Jan. 15, 2019 (GLOBE NEWSWIRE) -- OSE...